The comparative tissue distribution of ceforanide, cefazolin, and cefamandole was determined in rats after subcutaneous doses of 100 mg/kg. Ceforanide had the longest plasma half-life, 0.9 h, versus 0.5 h for cefazolin and 0.4 h for cefamandole, and the highest area under the plasma concentration time curve, 324 Ag.h per ml, versus 184 jig.h per ml for cefazolin and 42 ,ig.h per ml for cefamandole. The peak plasma concentrations of ceforanide and cefazolin were 173 and 140 ,Lg/ml, respectively, and were threefold higher than that of cefamandole (49 ,ug/ml). Measurable concentrations of the three compounds were found in the liver, kidneys, lungs, submaxillary glands, cervical lymph nodes, bones, heart, abdominal muscles, eyes, and testes, with cefamandole levels being generally lower and more variable. The peak tissue levels of ceforanide and cefazolin were comparable, within the limit of data variation, and were considerably higher than that of cefamandole. The tissue half-lives of these cephalosporins were similar to the respective plasma half-lives.
has a longer plasma half-life (tl/2) and larger area under the plasma concentration time curve (AUC). The slower elimination of ceforanide was due to slower body and renal clearances. Singleand multiple-dose clinical pharmacokinetic studies (5) demonstrated that the ceforanide plasma tl/2 of 3 h was longer than those of other parenteral cephalosporins, and there was no evidence of drug accumulation on multiple dosing. Ceforanide was not metabolized before elimination, and renal excretion was the major elimination route. The extended tl/2 permitted therapeutic dosing at 12-h intervals in contrast to 4-to 6-h intervals with other parenteral cephalosporins. The usual adult human therapeutic dose is 0.5 to 1.0 g, administered twice daily. Although plasma levels of an unmetabolized compound usually correlate with tissue concentrations, demonstration of extended tissue tl/2 in animals and humans would be of value in both prophylaxis and therapy of infectious diseases. This paper reports the tissue distribution of ceforanide and the reference compounds cefazolin and cefamandole relative to their plasma elimination kinetics in rats.
MATERLALS AND METHODS
Cephalosporins. Ceforanide (BL-S786R), the l-lysine salt of 7-(2-amino-methylphenylacetamido)-3-(1-carboxymethyltetrazol-5-yl-thiomethyl)-3-cephem-4-carboxylic acid, and cefazolin, the sodium salt of 3 Concentrations of the three compounds were measurable in the liver, kidneys, lungs, submaxillary glands, cervical lymph nodes, femur, heart, abdominal muscles, eyes, and testes. Cefamandole levels were generally lower and more variable (coefficient of variation, 58%). The tissue elimination kinetics followed the plasma elimination profiles ( Table 2) . As in the plasma, ceforanide had the longest average tissue elimination t1/2 (1.1 ± 0.2 h versus 0.7 ± 0.2 h for cefazolin and 0.7 ± 0.3 h for cefamandole), the most sustained antibiotic tissue concentrations, and the highest tissue AUC values. The tissue CG.. values of ceforanide and cefazolin were comparable, within the limit of data variation, and considerably higher than the cefamandole tissue Cmax (Table 1) .
No measurable ceforanide, cefazolin, and cefamandole concentrations (lower limits of assay sensitivity, c2.5 ,.g/g for ceforanide and cefazolin and c0.25 ,ug/g for cefamandole) were found in the brain, suggesting minimal penetration of these compounds through the noninflamed blood-brain barrier.
A comparison of available data on the human pharmacokinetics of ceforanide, cefazolin, and cefamandole (2, 4, 5, 7) indicated that ceforanide had the longest plasma tl/2 (2.6 to 3 h versus 2 h for cefazolin and 0.9 h for cefamandole) and the highest plasma AUC (707 ,tg.h per ml versus 560 ,tg-h per ml for cefazolin and 186 ,ug-h per ml for cefamandole), after 30-mg/kg intravenous doses. Although comparative clinical trials are necessary for conclusive assessment of the ther- showed that a 500-mg dose of ceforanide given every 12 h resulted in comparable antibiotic concentrations in the vaginal tissue of hysterectomy patients to a 1-g dose of cephalothin given every 4 to 6 h.
